uniQure Receives Additional $53M from Bristol-Myers Squibb for Target Selection Payment and Additional Equity Investment

uniQure N.V. QURE today announced the receipt of an additional $53 million from Bristol-Myers Squibb BMY in accordance with the companies' strategic collaboration to develop gene therapies to treat a range of cardiovascular diseases. Bristol-Myers Squibb selected three new collaboration targets triggering a $15 million cash payment to uniQure.    Bristol-Myers Squibb also acquired an additional 1.3 million ordinary shares of uniQure priced at $29.67 per share, providing net proceeds to the Company of approximately $38 million. The purchase price represents an approximately 26% premium over uniQure's closing price per ordinary share on August 7, 2015. After this second equity closing, Bristol-Myers Squibb owns 9.9% of uniQure's outstanding ordinary shares. "Our collaboration with Bristol-Myers Squibb has been progressing very well and we admire their drive and commitment to bringing transformational medicine, such as gene therapy, to patients with cardiovascular disease," said Joern Aldag, Chief Executive Officer of uniQure. "With the recent addition of more than $200 million in capital from our collaboration and the Company's recent follow-on offering, we have the financial resources to meet the needs of our collaboration and advance the development of our proprietary pipeline focused See full press release